Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma

NCT00492986 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00492986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00492986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2005
Completion date
November 30, 2008
Enrollment
1,150 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, renal cell